Ver el código de «Pyridostigmine»

==Administration==
*Type: Neostimine analogue, cholinesterase inhibitor
*Dosage Forms: oral immediate or extended release, IV
*Routes of Administration: IV, PO
*Common Trade Names:
*As opposed to [[physostigmine]], pyridostigmine does not cross the blood brain barrier, and is thus a poor agent for agitation and CNS complications

==Adult Dosing==
*[[Myasthenia gravis]]: 60-1500 mg PO daily (immediate release) or 180-540mg PO daily (slow-release)
*Reversal of [[neuromuscular blocking agents]]: 0.1-0.25 mg/kg IV
*Organophosphate poisoning prophylaxis: 30mg PO q8h

==Pediatric Dosing==

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]: Infant risk minimal
*Renal dosing: lower dose may be required, titrate to effect

==Contraindications==
*Allergy to class/drug
*Mechanical bowel or urinary obstruction

==Adverse Reactions==
===Serious===
*Cholinergic crisis
*[[Bradyarrythmia]]
===Common===
*[[Nausea/vomiting]], abdominal cramps, [[diarrhea]]
*Muscle cramps, fasciculation, asthenia
*Increased bronchial and salivary secretions

==Pharmacology==
*Half-life: 3 minutes (IV), 200 minutes (oral)
*Metabolism: 
*Excretion: Renal

==Mechanism of Action==
*Neostigmine analogue; competitive cholinesterase inhibitor→ less acetylcholine breakdown→ more available acetylcholine in synapses
==Comments==

==See Also==
*[[Neostigmine]]
*[[Neuromuscular blocking agents]]
*[[Myasthenia gravis]]

==References==
<references/>
[[Category:Pharmacology]]